Semazic SC Injection

Semazic SC Injection

Semaglutide is a GLP-1 analogue with 94% sequence as same as to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor.

Indications

For Diabetes: Semazic is indicated in-

• An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
  For Obesity: An adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
• 30 kg/m2 or greater (Obesity) or
• 27 kg/m2 or greater (Overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus or dyslipidemia).

Pharmacology

Semaglutide is a GLP-1 analogue with 94% sequence as same as to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor. Semaglutide reduces blood glucose in a glucose dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high.

Interaction

With medicine: Semazic delays gastric emptying which may influence the absorption of other oral medications. Trials were conducted to study the potential effect of Semazic on the absorption of oral medicinal products taken with Semazic administered orally at steady state exposure.

With food & others: Concomitant intake of food reduces the exposure of Semazic.

Contraindications

• Semaxen is contraindicated in patients who are hypersensitive to Semaxen or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
• Semaxen is contraindicated in patients who have a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Semaxen should not be used during pregnancy or breastfeeding.

Use in Special Populations

Pediatric population: The safety and efficacy of Semazic in children and adolescents below 18 years have not yet been established. No data are available.

Elderly: No dose adjustment is required based on age.

Renal impairment: No dose adjustment is required for patients with mild moderate or severe renal impairment. Semazic is not recommended for use in patients with end-stage renal disease.

Therapeutic Class

GLP-1 receptor agonists

Storage Conditions

Injection: Store at 2°C to 8°C (in a refrigerator). Do not freeze. Keep away from light. Keep all the medicine out of the reach of children.Tablet: Store below 30°C, in a cool and dry place. Keep away from light. Keep all the medicine out of the reach of children.